Devacell, Inc.
San Diego, CA, US· latest recorded location
Devacell, Inc. is named on 1 US grants and 4 published applications in this corpus. Its most frequent classification is A61K (Medicines and medical preparations).
- Granted patents
- 1
- Published applications
- 4
- Inventors
- 4
- Granted in 2026 so far
- 0
- Most recent grant
- 28 May 2019
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2016 | 0 | 1 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 1 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 0 | 2 |
| 2024 | 0 | 1 |
By publication year.
Technology areas
Share of 5 documents
Recent patents
- Recombinant oncolytic viruses, surface-engineered delivery systems and related methods25 Jan 2024US 2024/0026305 A1
- Recombinant viruses, surface-engineered delivery systems and related methods16 Nov 2023US 2023/0364222 A1
- Recombinant viruses, surface-engineered delivery systems and related methods31 Aug 2023US 2023/0272420 A1
- Enzyme-encapsulated nanoparticle platform25 Aug 2016US 2016/0243262 A1
Most cited
By later US patents
None of its patents has been cited by a later US patent yet.